



Lundbeck LLC

July 14, 2017

Re: Important: Discontinuation of Frisium® (clobazam) Tablets in Canada

Dear Healthcare Professional and Epilepsy Patient Advocacy Organization,

After careful consideration, Lundbeck has made the decision to discontinue the manufacturing of Frisium® (clobazam) Tablets in Canada. Based on historical demand, we expect our current inventory to be depleted by the end of 2018. This decision was not triggered by a safety issue, but rather is based on the numerous generic clobazam alternatives available in Canada.

Lundbeck is communicating this change more than a year in advance in order to give healthcare professionals, patients and families as much advance notice as possible so that Frisium patients have ample time to successfully shift to an acceptable alternative clobazam therapy. Health Canada also has been notified.

As a company with a strong record of supporting the epilepsy community, Lundbeck is aware of the ongoing struggles many physicians and their patients experience in managing seizures. We are deeply committed to the epilepsy community, which is why we are taking a number of steps to ease this transition, including:

- Access to Lundbeck's Medical Information team at 866-880-4636 to address questions or concerns. We will closely monitor responses from patients, their families and healthcare professionals and address concerns appropriately.
- Distribution of a discontinuation letter to a comprehensive list of physicians, pharmacists and patient advocacy organizations throughout Canada in July 2017, providing more than a year's lead time to enable a carefully thought-through treatment transition plan.
 - Follow-up reminder letters are scheduled for January 2018 and October 2018.
 - Patient advocacy organizations will be encouraged to share this notice for use in on- and offline communications materials, as appropriate.
- Outreach to pharmaceutical wholesalers.
- Updates to generic clobazam manufacturers to ensure awareness of our plans and timeline.

Again, please contact Lundbeck Medical Information at 866-880-4636 if you have any questions.

Sincerely,

A handwritten signature in black ink, appearing to read 'D. Williamson', with a long horizontal line extending to the right.

Doug Williamson, MD
Chief Medical Officer, VP US Drug Development
Lundbeck